John K. A.  Prendergast net worth and biography

John Prendergast Biography and Net Worth

John Prendergast is co-founder of Palatin Technologies, a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. He has been chairman of the board at Palatin since June 2000 and director since August 1996. Dr. Prendergast is also president of Summercloud Bay, an independent consulting firm providing services to the biotechnology industry, and director and executive board chairman of Antyra, a privately-held biopharmaceutical firm. From 1991 through 1997, he was managing director of The Castle Group Ltd., a medical venture capital firm. Dr. Prendergast received his M.Sc. and Ph.D. from the University of New South Wales, and a C.S.S. in administration and management from Harvard University.

What is John K. A. Prendergast's net worth?

The estimated net worth of John K. A. Prendergast is at least $0.00 as of May 14th, 2021. Mr. Prendergast owns 203,272 shares of NightHawk Biosciences stock worth more than $0 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Prendergast may own. Learn More about John K. A. Prendergast's net worth.

How do I contact John K. A. Prendergast?

The corporate mailing address for Mr. Prendergast and other NightHawk Biosciences executives is 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560. NightHawk Biosciences can also be reached via phone at 919-240-7133 and via email at [email protected]. Learn More on John K. A. Prendergast's contact information.

Has John K. A. Prendergast been buying or selling shares of NightHawk Biosciences?

John K. A. Prendergast has not been actively trading shares of NightHawk Biosciences during the last ninety days. Most recently, John K. A. Prendergast sold 35,000 shares of the business's stock in a transaction on Friday, May 14th. The shares were sold at an average price of $5.87, for a transaction totalling $205,450.00. Following the completion of the sale, the director now directly owns 203,272 shares of the company's stock, valued at $1,193,206.64. Learn More on John K. A. Prendergast's trading history.

John K. A. Prendergast Insider Trading History at NightHawk Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2021Sell35,000$5.87$205,450.00203,272View SEC Filing Icon  
See Full Table

John K. A. Prendergast Buying and Selling Activity at NightHawk Biosciences

This chart shows John K A Prendergast's buying and selling at NightHawk Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NightHawk Biosciences Company Overview

NightHawk Biosciences logo
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.39
Low: $0.26
High: $0.50

2 Week Range

Now: N/A

Volume

173,100 shs

Average Volume

97,242 shs

Market Capitalization

$10.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19